Live Analyst Rating Changes 23586 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andrew Berens
LP

Andrew Berens

Wall Street Analyst
★★★★★
#312
on 13Foresight · ranked by our own returns
69%
Success Rate
+35.2%
Average Return
29 of 42 calls profitable · +22.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 69% of Andrew Berens's ratings turned a profit when each position was held for 1 year — averaging +35.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

40 Buy 7 Hold 0 Sell
Andrew's Stock Coverage 40 ratings · 2026-08-12
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
CMPX
Compass Therapeutics
Aug 07, 2026 BUY Strong Buy
+323.8% avg upside
20 analysts
$7.00
218.20% Upside
+2.3% ·
EXEL
Exelixis
Aug 06, 2026 HOLD Buy
-15.5% avg upside
34 analysts
$52.00
1.21% Upside
-3.5% ·
INCY
Incyte
Aug 03, 2026 BUY Buy
-11.2% avg upside
47 analysts
$155.00
28.02% Upside
+2.0% ·
AGIO
Agios Pharma
Jul 07, 2026 BUY Strong Buy
+89.3% avg upside
29 analysts
-22.7% ·
PBLS
Parabilis Medicines, Inc.
Jul 06, 2026 BUY Strong Buy
+23.3% avg upside
6 analysts
$40.00
9.68% Upside
+19.8% ·
AURA
Aura Biosciences Inc
Jun 02, 2026 BUY Strong Buy
+157.2% avg upside
9 analysts
+11.6% ·
STRO
Sutro Biopharma
May 15, 2026 BUY Strong Buy
+57.7% avg upside
21 analysts
$43.00
71.63% Upside
-34.5% ·
DMRA
Damora Therapeutics
May 15, 2026 BUY Strong Buy
-4.7% avg upside
20 analysts
$51.00
67.96% Upside
+21.6% ·
IMNM
Immunome
May 15, 2026 BUY Strong Buy
+29.4% avg upside
16 analysts
$33.00
25.74% Upside
+19.9% ·
TNGX
Tango Therapeutics
May 15, 2026 BUY Strong Buy
+45.7% avg upside
15 analysts
$55.00
108.90% Upside
+29.0% ·
ANL
Adlai Nortye Ltd. Sponsored ADR
Mar 20, 2026 BUY Strong Buy
+64.9% avg upside
7 analysts
$23.00
75.77% Upside
+79.5% ·
BBOT
BridgeBio Oncology Therapeutics
Mar 06, 2026 BUY Strong Buy
+172.3% avg upside
10 analysts
$41.00
345.66% Upside
-10.9% ·
RLMD
Relmada Therapeutics
Jan 23, 2026 BUY Buy
+206.4% avg upside
15 analysts
$8.00
79.02% Upside
+16.4% ·
ZYME
Zymeworks
Nov 19, 2025 BUY Strong Buy
+36.3% avg upside
25 analysts
$40.00
64.42% Upside
+7.6% ·
CELC
Celcuity
Nov 17, 2025 BUY Strong Buy
+40.5% avg upside
16 analysts
$97.00
10.02% Upside
-1.6% ·
COGT
Cogent Biosciences
Nov 10, 2025 BUY Strong Buy
-4.4% avg upside
26 analysts
$50.00
29.24% Upside
+19.3% ·
IMRX
Immuneering
Oct 31, 2025 BUY Strong Buy
+287.5% avg upside
12 analysts
$15.00
212.47% Upside
-34.1% ·
IDYA
IDEAYA Biosciences
Oct 21, 2025 HOLD Strong Buy
+31.5% avg upside
29 analysts
$33.00
10.43% Downside
+25.8% ·
CGEM
Cullinan Management
Sep 04, 2025 BUY Strong Buy
+73.8% avg upside
15 analysts
+183.2% ·
OKUR
OnKure Therapeutics
Aug 13, 2025 BUY Buy
+480.9% avg upside
13 analysts
$33.00
706.76% Upside
+72.5% ·
RLAY
Relay Therapeutics
Aug 12, 2025 BUY Strong Buy
+8.6% avg upside
21 analysts
$12.00
39.89% Downside
+490.2% ·
BOLD
Boundless Bio Inc.
Aug 11, 2025 HOLD Hold
+227.3% avg upside
11 analysts
$3.00
9.03% Upside
+160.4% ·
ZNTL
Zentalis Pharmaceuticals
Aug 07, 2025 HOLD Buy
+239.3% avg upside
18 analysts
$5.00
21.72% Upside
+191.0% ·
ARVN
Arvinas Holding Company
Aug 07, 2025 HOLD Buy
+219.9% avg upside
28 analysts
$9.00
0.16% Upside
+40.2% ·
ONC
BeOne Medicines
Aug 07, 2025 BUY Strong Buy
+0.8% avg upside
28 analysts
$345.00
4.00% Downside
+16.8% ·
HK:2256
Abbisko Cayman Limited
Aug 05, 2025 BUY Strong Buy
+99.3% avg upside
3 analysts
$18.00
59.11% Upside
-14.8% ·
GH
Guardant Health
Feb 26, 2025 BUY Strong Buy
-1.1% avg upside
31 analysts
+126.8% ·
ASH
Ashland
Dec 10, 2024 BUY Strong Buy
+4.8% avg upside
16 analysts
-18.7% ·
CCCC
C4 Therapeutics
Feb 07, 2023 BUY Strong Buy
+373.5% avg upside
19 analysts
$25.00
545.94% Upside
-12.7% ·
GLUE
Monte Rosa Therapeutics
Feb 07, 2023 HOLD Strong Buy
+41.0% avg upside
15 analysts
$15.00
4.81% Downside
-40.0% ·
SVRN
OceanPal Inc
Mar 21, 2022 BUY Buy
6 analysts
· ·
PBYI
Puma Biotechnology
May 07, 2021 HOLD Hold
+382.4% avg upside
11 analysts
$10.00
14.10% Upside
-79.7% ·
NBRVF
Nabriva Therapeutics
Jan 17, 2018 BUY Buy
+13374900.0% avg upside
9 analysts
$10.00
9999900.09% Upside
· ·
RYTM
Rhythm Pharmaceuticals
Nov 01, 2017 HOLD Strong Buy
+9.6% avg upside
20 analysts
$23.00
79.58% Downside
+10.7% ·
OCUL
Ocular Therapeutix
Jul 14, 2017 HOLD Strong Buy
+156.3% avg upside
21 analysts
$8.00
18.07% Downside
+3.6% ·
RMTI
Rockwell Med
Jul 18, 2016 SELL Buy
+124.2% avg upside
11 analysts
· ·
AKBA
Akebia Therapeutics
Jul 18, 2016 BUY Strong Buy
+984.4% avg upside
16 analysts
+61.2% ·
CG
Carlyle Group
Feb 17, 2016 BUY Buy
+15.8% avg upside
25 analysts
$20.00
58.73% Downside
+24.4% ·
ENTA
Enanta Pharmaceuticals
Dec 01, 2014 HOLD Buy
+142.0% avg upside
17 analysts
-28.3% ·
GILD
Gilead Sciences
Dec 01, 2014 HOLD Strong Buy
-12.1% avg upside
66 analysts
+6.1% ·
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Andrew Berens — Frequently Asked Questions
How accurate are Andrew Berens's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Andrew's ratings were profitable over a one-year hold, with an average return of +35.2% per rating, or +22.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Andrew ranked on 13Foresight?
Andrew Berens is currently ranked #312 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andrew cover?
Andrew most recently has ratings on CMPX, EXEL, INCY, AGIO, PBLS, AURA, STRO, DMRA, IMNM, TNGX, ANL, BBOT and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.